

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 77,974,229

Date: May 4th, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.
 - **The pandemic is entering an endemic stage as restrictions are being lifted. There are still concerns of infection rates due to the Omricon BA.1 and BA.2 variants that are still spreading globally. The company remains hopeful but vigilant. Financial, operational and recovery measures instituted by the management team aided in sustaining business viability over the past 24 months and the company intends to navigate through the endemic phase diligently.**
 - **BioMark submitted a manuscript titled "Spermidine/spermine N1-acetyltransferase 1 (SAT1) – A Gene Target for Selective Sensitization of GBM Cells using an Ionizable Lipid Nanoparticle to Deliver siRNA." through the collaboration with Dr. Don Miller and his group at the Department of Pharmacology & Therapeutics, Kleysen Institute for Advanced Medicine University of Manitoba to a high impact special edition peer review medical journal. The corresponding authors are responding to a final request from the editor in chief of the journal. Shipping delays involving materials to complete the experiment resulted in the delay. BioMark remains confident that the paper will be accepted for publication soon.**
 - **Further dialogue with the French group TransDiag is scheduled for early week in May 2022. TransDiag is led by a group of biopharma experienced partners and are looking at reviewing and establishing a lung cancer screening platform for France and have high confidence in BioMark's early lung cancer liquid biopsy panel. Potential meetings are planned for later in May in France with BioMark's business development specialist.**

- **BioMark will be receiving another set of plasma samples from its collaboration with the University of Brescia in Italy under Dr. Paolo Bossi as principal investigator for the study titled “IDENTIFICATION OF CIRCULATING MARKERS TO CUSTOMIZE THE FOLLOW-UP OF HEAD AND NECK CANCER PATIENTS FOR EARLY IDENTIFICATION OF RECURRENCES/SECOND TUMORS”. Analysis will be performed at The Metabolomics Innovation Centre using a special mega panel for this important discovery and validation phase of the study.**
- **As part of its previously announced retrospective study, BioMark is collaborating with TMIC to complete analysis of about 1000 plasma samples, which also includes other lung diseases, covid cases and other cancers. The first data readout is expected by early June 2022.**
- **BioMark registered for BIO International Convention 2022 that will be held June 13-16, 2022, in San Diego, CA. BioMark is in the process of arranging several one-on-one meetings with potential investors, strategic biopharma and lab collaborators/partners. Quebec government partially sponsored BioMark’s participation and has provided access to its booth at the Canadian pavilion.**
- **BioMark discovery study in breast cancer is being further refined using the latest advancement in machine learning algorithm. Preliminary data look very encouraging, and discussions have commenced with a large biopharma for use of our biomarker as a companion diagnostic application.**
- **BioMark continued to entertain discussions various financial institutions and government agencies to secure non-dilutive funding, favourable loans and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise and to advance its expansion strategy in Quebec and the USA and for general corporate purposes.**

- The company has reached out to 3 major medical institutions in United States as it begins to pursue its US expansion plans. Business partnership activities are being explored to conduct clinical trials and establish new centres of excellence for early lung cancer screening. Clinical study designs and protocols have been submitted to respective institutional review board (IRB) at the institution for approval prior to signing of agreements between the parties. Ethics approval is anticipated soon.
 - BioMark continues to be invited to discuss the company, its technology platform, and developments in several high-profile podcasts in Canada and the USA. The latest podcast was with Biotech Bros and will be released by mid may. Links will be shared via LinkedIn and on the website. The podcast was targeted towards US retail investors
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- Not applicable.**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- Not applicable.**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
- Not applicable.**
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- Not applicable.**

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 4

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 5

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2021.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 4th, 2022.

Rashid Ahmed Maula Bux
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"
Signature

President & CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer	April, 2022	YY/MM/DD
BioMark Diagnostics Inc.		2022/05/04
Issuer Address		
130 - 3851 Shell Road		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Richmond, BC, V6X 2W2	N/A	(604) 370-0779
Contact Name	Contact Position	Contact Telephone No.
Rashid Ahmed Bux	CEO	(604) 370-0779
Contact Email Address	Web Site Address	
info@biomarkdiagnostics.com	www.biomarkdiagnostics.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 7